EA200401341A1 - Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания - Google Patents

Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания

Info

Publication number
EA200401341A1
EA200401341A1 EA200401341A EA200401341A EA200401341A1 EA 200401341 A1 EA200401341 A1 EA 200401341A1 EA 200401341 A EA200401341 A EA 200401341A EA 200401341 A EA200401341 A EA 200401341A EA 200401341 A1 EA200401341 A1 EA 200401341A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteoprotegerin
prevention
treatment
application
fibrous disease
Prior art date
Application number
EA200401341A
Other languages
English (en)
Other versions
EA007927B1 (ru
Inventor
Кристин Пауэр
Кристине Платер-Циберк
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н. В. filed Critical Апплайд Резеч Системз Арс Холдинг Н. В.
Publication of EA200401341A1 publication Critical patent/EA200401341A1/ru
Publication of EA007927B1 publication Critical patent/EA007927B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

Изобретение относится к применению остеопротегерина для лечения и/или профилактики фиброзных заболеваний, в частности склеродермии.Отчет о международном поиске был опубликован 2004.02.05.
EA200401341A 2002-04-10 2003-03-26 Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания EA007927B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100364 2002-04-10
PCT/EP2003/050080 WO2003084560A2 (en) 2002-04-10 2003-03-26 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis

Publications (2)

Publication Number Publication Date
EA200401341A1 true EA200401341A1 (ru) 2005-06-30
EA007927B1 EA007927B1 (ru) 2007-02-27

Family

ID=28685985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401341A EA007927B1 (ru) 2002-04-10 2003-03-26 Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания

Country Status (18)

Country Link
US (1) US7638480B2 (ru)
EP (1) EP1515743A2 (ru)
JP (1) JP4430403B2 (ru)
KR (1) KR20040107492A (ru)
CN (1) CN1658895A (ru)
AU (1) AU2003240754B2 (ru)
BR (1) BR0309095A (ru)
CA (1) CA2480084A1 (ru)
EA (1) EA007927B1 (ru)
HR (1) HRP20040877A2 (ru)
IL (1) IL164463A (ru)
MX (1) MXPA04009884A (ru)
NO (1) NO20044658L (ru)
PL (1) PL372928A1 (ru)
RS (1) RS89204A (ru)
UA (1) UA86345C2 (ru)
WO (1) WO2003084560A2 (ru)
ZA (1) ZA200407655B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663294B1 (en) * 2003-09-08 2008-03-26 Laboratoires Serono SA Treatment of fibrotic disease
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
KR101250364B1 (ko) * 2004-12-13 2013-04-05 세파론 오스트레일리아 (브이아이씨) 피티와이 엘티디 오스테오프로테게린 변이체 단백질
CN101432626B (zh) 2006-04-04 2013-06-19 神谷来克斯公司 用于肌钙蛋白分析的高灵敏系统和方法
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
WO2009021190A2 (en) * 2007-08-08 2009-02-12 Renovar, Inc. Systems and methods for characterizing lupus erythematosus
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
KR102578891B1 (ko) 2012-05-11 2023-09-15 주식회사 젬백스앤카엘 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
CN104487091A (zh) * 2012-05-22 2015-04-01 夏尔人类遗传性治疗公司 用于治疗硬皮病的抗ccl2抗体
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
JP2017508792A (ja) * 2014-03-06 2017-03-30 アール−ファーム・オーバーシーズ・インコーポレイテッドＲ−Ｐｈａｒｍ Ｏｖｅｒｓｅａｓ， Ｉｎｃ． オステオプロテゲリンはランケル・インヒビターを引き出した
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
CN105944082B (zh) * 2016-06-13 2017-08-25 浙江生创精准医疗科技有限公司 骨保护素单独或与其他细胞因子联合在治疗肝纤维化中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
AU1235692A (en) 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
EP0954580B1 (en) * 1997-02-06 2003-12-17 Genetics Institute, LLC Human sdf-5 protein and compositions
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2001017543A2 (en) * 1999-09-03 2001-03-15 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
HRP20030426A2 (en) 2000-12-06 2005-04-30 Applied Research Systems Ars Holding N.V. Use of sarp-1 for the treatment and/or preventionof scleroderma
EP1270015A3 (en) 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease

Also Published As

Publication number Publication date
UA86345C2 (ru) 2009-04-27
KR20040107492A (ko) 2004-12-20
PL372928A1 (en) 2005-08-08
BR0309095A (pt) 2005-02-09
CN1658895A (zh) 2005-08-24
EP1515743A2 (en) 2005-03-23
MXPA04009884A (es) 2004-12-07
IL164463A (en) 2011-09-27
WO2003084560A2 (en) 2003-10-16
ZA200407655B (en) 2005-11-02
NO20044658L (no) 2004-10-28
US20060003928A1 (en) 2006-01-05
AU2003240754B2 (en) 2009-02-26
IL164463A0 (en) 2005-12-18
HRP20040877A2 (en) 2005-02-28
RS89204A (sr) 2006-12-15
JP4430403B2 (ja) 2010-03-10
US7638480B2 (en) 2009-12-29
AU2003240754A1 (en) 2003-10-20
CA2480084A1 (en) 2003-10-16
WO2003084560A3 (en) 2004-02-05
EA007927B1 (ru) 2007-02-27
JP2005530720A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
BRPI0307673A2 (pt) métodos de tratar doença vascular.
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
TR200101772T2 (tr) IL-8 Reseptörü antagonistleri olarak hidroksi difenil üre sülfonamidler
NO20034056D0 (no) Proliferative sykdommer
EA200500856A1 (ru) Новые химические соединения
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
EE200400005A (et) Tablett, mis sisaldab vähemalt kahte eristatavat segmenti ning selle kasutamine
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
DK1532131T3 (da) Motilid-forbindelser
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU